e-ISSN: 2394-2967
logo

British Journal of Medical and Health Research

LoginTrack

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

Volume 11, Issue 1 - 2024 (January 2024 Issue 1)

Volume 11 Issue 1 Cover

Issue Details:

Volume 11 Issue 1
Published:Invalid Date

Editorial: January 2024 Issue 1

Welcome to the 2024 issue of British Journal of Medical and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr Hemangi J Patel
Editor-in-Chief
British Journal of Medical and Health Research

Articles in This Issue

Showing 2 of 2 articles
Research PaperID: BJMHR1101001

Analysis of Early Results of Surgical Treatment of Muscle-Invasive Bladder Cancer

D.M. Tursunov, D.Z. Mamarasulova

ABSTRACT Invasive bladder cancer is a cancer that is becoming increasingly common among men. Radical cystectomy is widely used as the primary treatment for this type of tumor. In order to improve the quality of life of patients, which is no less important than the survival rate, specialists in modern practical oncology have introduced more than 46 types of urine diversion into practice in the period after such highly traumatic operations. Complications after these operations and the problem of their elimination also remain relevant. Keywords: Radical cystectomy, complications, invasive bladder cancer, neocystoplasty, Studer orthotopic neobladder, Hautmann orthotopic neobladder ileal conduit.

Radical cystectomycomplicationsinvasive bladder cancerneocystoplastyStuder orthotopic neobladderHautmann orthotopic neobladder ileal conduit
58,643 views
17,552 downloads
DOI:
10.5281/zenodo.10907202

Contributors:

 D.M. Tursunov
,
 D.Z. Mamarasulova
Research PaperID: BJMHR1101002

Role of Prophylactic Use of Propranolol In Prevention of ROP In Premature Neonates.

Subhash Walinjkar, Hemangi Reddy, Nikhil Gavhane, Rohit Telap, Pawan Bahekar, Shivani Deshmukh

ABSTRACT Retinopathy of prematurity (ROP) was known as Retrolental Fibroplasia is a leading cause of blindness among Premature Neonates. ROP is disorder of retinal blood vessels due to abnormal response of Premature Neonates retinal vasculature to prematurity and oxygen therapy for its management. Incidence and severity of ROP increases with decreasing birth weight and gestational age. Early identification and timely screening of neonates with risk factors helps to provide an opportunity for effective treatment. Beta blockers, most commonly propranolol, has been suggested for early prevention of ROP and treatment of existing ROP in preterm neonates. This study is to determine the role of prophylactic Oral Propranolol in prevention of ROP in Premature Neonates (26-35weeks GA) and to compare incidence of ROP in Premature Neonates (26-35weeks GA) receiving Oral Propranolol with one receiving Placebo. This is a comparative observational study conducted in the NICU of Rural Tertiary Care Hospital. The study includes Premature Neonates 26-35 weeks of Gestational Age (GA), grouped in ratio 1:1 with one group receiving Oral Propranolol and other Placebo which were followed for ROP screening 4 weeks after Postnatal Age. There is less incidence of diagnosis of ROP in Premature Neonates receiving Oral Propranolol. Hence such Premature Neonates require less therapeutic intervention in future. Thus, Oral Propranolol is an effective treatment in the management of ROP in Premature Neonates thereby decreasing the incidence of Progression and severity of ROP. Keywords: ROP, Premature Neonates, Oral Propranolol, Anti-VEGF, PRP laser.

ROPPremature NeonatesOral PropranololAnti-VEGFPRP laser.
58,773 views
17,670 downloads
DOI:
10.5281/zenodo.10907223

Contributors:

 Subhash Walinjkar
,
 Hemangi Reddy
,
 Nikhil Gavhane
,
 Rohit Telap
,
 Pawan Bahekar
,
 Shivani Deshmukh

Related Issues

Volume 13, Issue 1

2026 • 2 articles

Volume 12, Issue 12

2025 • 2 articles

Volume 12, Issue 11

2025 • 2 articles

Volume 12, Issue 10

2025 • 2 articles